SENATE BILL No. 80

DIGEST OF INTRODUCED BILL

Citations Affected: IC 10-11-2-31.5; IC 25-26-13-4; IC 34-30-2-152.3; IC 35-31.5-2-106.5; IC 35-48-4.

Synopsis: Pharmacists and ephedrine. Defines "drug related felony", and requires courts to report drug related felonies to the state police department. Requires the state police department to report drug related felonies to NPLEx so that NPLEx can generate a stop sale alert to prevent individuals with drug related felonies from purchasing ephedrine or pseudoephedrine. Provides that the offense of possession of a precursor by a methamphetamine offender (which prohibits the possession of pseudoephedrine or ephedrine without a prescription by persons convicted of certain offenses) applies to a person who has been convicted of a drug related felony. Allows a pharmacist to deny the sale of ephedrine or pseudoephedrine on the basis of the pharmacist's professional judgment, and provides the pharmacist with civil immunity for making such a denial. Allows the Indiana board of pharmacy to: (1) adopt rules regarding professional determinations made; (2) review professional determinations made; and (3) discipline a pharmacist for a professional determination made; concerning refusal to sell ephedrine or pseudoephedrine.

Effective: July 1, 2016.

Head, Merritt

 ${\it January\,5,2016, read\,first\,time\,and\,referred\,to\,Committee\,on\,Family\,\&\,Children\,Services.}$



Second Regular Session 119th General Assembly (2016)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in this style type, and deletions will appear in this style type.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in **this style type**. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in a statute in *this style type* or *this style type* reconciles conflicts between statutes enacted by the 2015 Regular Session of the General Assembly.

SENATE BILL No. 80

A BILL FOR AN ACT to amend the Indiana Code concerning professions and occupations.

Be it enacted by the General Assembly of the State of Indiana:

1	SECTION 1. IC 10-11-2-31.5 IS ADDED TO THE INDIANA
2	CODE AS A NEW SECTION TO READ AS FOLLOWS
3	[EFFECTIVE JULY 1, 2016]: Sec. 31.5. (a) As used in this section,
4	"drug related felony" has the meaning set forth in
5	IC 35-48-4-18(a).
6	(b) The superintendent shall:
7	(1) receive reports from courts regarding drug related
8	felonies;
9	(2) notify the National Precursor Log Exchange (NPLEx) of
10	each drug related felony entered within the previous seven (7)
11	years and provide the following information:
12	(A) the convicted individual's full name;
13	(B) the convicted individual's date of birth;
14	(C) the convicted individual's driver's license number or
15	state personal identification number; and
16	(D) the date the individual was convicted of the drug
17	related felony;



1	(3) request that a stop sale alert be generated through the
2	National Precursor Log Exchange (NPLEx) for each
3	individual reported under subdivision (2); and
4	(4) notify the National Precursor Log Exchange (NPLEx):
5	(A) if the drug related felony of an individual reported
6	under subdivision (2) has been:
7	(i) set aside;
8	(ii) reversed;
9	(iii) expunged; or
10	(iv) vacated; and
11	(B) if clause (A) applies, that a stop sale alert should not be
12	issued for the individual.
13	SECTION 2. IC 25-26-13-4, AS AMENDED BY P.L.182-2009(ss),
14	SECTION 371, IS AMENDED TO READ AS FOLLOWS
15	[EFFECTIVE JULY 1, 2016]: Sec. 4. (a) The board may:
16	(1) promulgate rules and regulations under IC 4-22-2 for
17	implementing and enforcing this chapter;
18	(2) establish requirements and tests to determine the moral,
19	physical, intellectual, educational, scientific, technical, and
20	professional qualifications for applicants for pharmacists'
21	licenses;
22	(3) refuse to issue, deny, suspend, or revoke a license or permit or
23	place on probation or fine any licensee or permittee under this
24	chapter;
25	(4) regulate the sale of drugs and devices in the state of Indiana;
26	(5) impound, embargo, confiscate, or otherwise prevent from
27	disposition any drugs, medicines, chemicals, poisons, or devices
28	which by inspection are deemed unfit for use or would be
29	dangerous to the health and welfare of the citizens of the state of
30	Indiana; the board shall follow those embargo procedures found
31	in IC 16-42-1-18 through IC 16-42-1-31, and persons may not
32	refuse to permit or otherwise prevent members of the board or
33	their representatives from entering such places and making such
34	inspections;
35	(6) prescribe minimum standards with respect to physical
36	characteristics of pharmacies, as may be necessary to the
37	maintenance of professional surroundings and to the protection of
38	the safety and welfare of the public;
39	(7) subject to IC 25-1-7, investigate complaints, subpoena
10	witnesses, schedule and conduct hearings on behalf of the public
11	interest on any matter under the jurisdiction of the board;
12	(8) prescribe the time, place, method, manner, scope, and subjects



1	of licensing examinations which shall be given at least twice
2	annually; and
3	(9) perform such other duties and functions and exercise such
4	other powers as may be necessary to implement and enforce this
5	chapter.
6	(b) The board shall adopt rules under IC 4-22-2 for the following:
7	(1) Establishing standards for the competent practice of
8	pharmacy.
9	(2) Establishing the standards for a pharmacist to counsel
0	individuals regarding the proper use of drugs.
1	(3) Establishing standards and procedures before January 1, 2006,
2	to ensure that a pharmacist:
3	(A) has entered into a contract that accepts the return of
4	expired drugs with; or
5	(B) is subject to a policy that accepts the return of expired
6	drugs of;
7	a wholesaler, manufacturer, or agent of a wholesaler or
8	manufacturer concerning the return by the pharmacist to the
9	wholesaler, the manufacturer, or the agent of expired legend drugs
0.0	or controlled drugs. In determining the standards and procedures,
21	the board may not interfere with negotiated terms related to cost,
22	expenses, or reimbursement charges contained in contracts
23	between parties, but may consider what is a reasonable quantity
.4	of a drug to be purchased by a pharmacy. The standards and
22 23 24 25 26	procedures do not apply to vaccines that prevent influenza,
26	medicine used for the treatment of malignant hyperthermia, and
27	other drugs determined by the board to not be subject to a return
28	policy. An agent of a wholesaler or manufacturer must be
.9	appointed in writing and have policies, personnel, and facilities
0	to handle properly returns of expired legend drugs and controlled
1	substances.
2	(c) The board may grant or deny a temporary variance to a rule it
3	has adopted if:
4	(1) the board has adopted rules which set forth the procedures and
5	standards governing the grant or denial of a temporary variance;
6	and
7	(2) the board sets forth in writing the reasons for a grant or denial
8	of a temporary variance.
9	(d) The board shall adopt rules and procedures, in consultation with
0	the medical licensing board, concerning the electronic transmission of

prescriptions. The rules adopted under this subsection must address the



41

42

following:

1	(1) Privacy protection for the practitioner and the practitioner's
2	patient.
3	(2) Security of the electronic transmission.
4	(3) A process for approving electronic data intermediaries for the
5	electronic transmission of prescriptions.
6	(4) Use of a practitioner's United States Drug Enforcement
7	Agency registration number.
8	(5) Protection of the practitioner from identity theft or fraudulent
9	use of the practitioner's prescribing authority.
10	(e) The governor may direct the board to develop:
11	(1) a prescription drug program that includes the establishment of
12	criteria to eliminate or significantly reduce prescription fraud; and
13	(2) a standard format for an official tamper resistant prescription
14	drug form for prescriptions (as defined in IC 16-42-19-7(1)).
15	The board may adopt rules under IC 4-22-2 necessary to implement
16	this subsection.
17	(f) The standard format for a prescription drug form described in
18	subsection (e)(2) must include the following:
19	(1) A counterfeit protection bar code with human readable
20	representation of the data in the bar code.
21	(2) A thermochromic mark on the front and the back of the
22 23 24 25 26 27	prescription that:
23	(A) is at least one-fourth (1/4) of one (1) inch in height and
24	width; and
25	(B) changes from blue to clear when exposed to heat.
26	(g) The board may contract with a supplier to implement and
27	manage the prescription drug program described in subsection (e). The
28	supplier must:
29	(1) have been audited by a third party auditor using the SAS 70
30	audit or an equivalent audit for at least the three (3) previous
31	years; and
32	(2) be audited by a third party auditor using the SAS 70 audit or
33	an equivalent audit throughout the duration of the contract;
34	in order to be considered to implement and manage the program.
35	(h) The board may:
36	(1) adopt rules under IC 4-22-2 regarding professional
37	determinations made;
38	(2) review determinations made by a pharmacist; and
39	(3) take appropriate disciplinary action against a pharmacist
40	for a determination made;
41	under IC 35-48-4-14.7 concerning the sale of ephedrine and
42	pseudoephedrine.



1	SECTION 3. IC 34-30-2-152.3, AS AMENDED BY P.L.193-2013
2	SECTION 1, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
3	JULY 1, 2016]: Sec. 152.3. (a) IC 35-48-4-14.7 IC 35-48-4-14.7(d)
4	and IC 35-48-4-14.7(k) (Concerning a pharmacy or NPLEx retailed
5	who discloses information concerning the sale of a product containing
6	ephedrine or pseudoephedrine).
7	(b) IC 35-48-4-14.7(d)(3) (Concerning a pharmacist's
8	professional judgment not to sell ephedrine or pseudoephedrine to
9	an individual).
10	SECTION 4. IC 35-31.5-2-106.5 IS ADDED TO THE INDIANA
l 1	CODE AS A NEW SECTION TO READ AS FOLLOWS
12	[EFFECTIVE JULY 1, 2016]: Sec. 106.5. "Drug related felony", for
13	purposes of IC 35-48-4-18, has the meaning set forth in
14	IC 35-48-4-18(a).
15	SECTION 5. IC 35-48-4-14.5, AS AMENDED BY P.L.168-2014
16	SECTION 105, IS AMENDED TO READ AS FOLLOWS
17	[EFFECTIVE JULY 1, 2016]: Sec. 14.5. (a) As used in this section
18	"chemical reagents or precursors" refers to one (1) or more of the
19	following:
20	(1) Ephedrine.
21	(2) Pseudoephedrine.
22	(3) Phenylpropanolamine.
23	(4) The salts, isomers, and salts of isomers of a substance
24	identified in subdivisions (1) through (3).
25	(5) Anhydrous ammonia or ammonia solution (as defined in
26	IC 22-11-20-1).
27	(6) Organic solvents.
28	(7) Hydrochloric acid.
29	(8) Lithium metal.
30	(9) Sodium metal.
31	(10) Ether.
32	(11) Sulfuric acid.
33	(12) Red phosphorous.
34	(13) Iodine.
35	(14) Sodium hydroxide (lye).
36	(15) Potassium dichromate.
37	(16) Sodium dichromate.
38	(17) Potassium permanganate.
39	(18) Chromium trioxide.
10	(19) Benzyl cyanide.
11	(20) Phenylacetic acid and its esters or salts.
12	(21) Piperidine and its salts.



1	(22) Methylamine and its salts.
2	(23) Isosafrole.
3	(24) Safrole.
4	(25) Piperonal.
5	(26) Hydriodic acid.
6	(27) Benzaldehyde.
7	(28) Nitroethane.
8	(29) Gamma-butyrolactone.
9	(30) White phosphorus.
10	(31) Hypophosphorous acid and its salts.
11	(32) Acetic anhydride.
12	(33) Benzyl chloride.
13	(34) Ammonium nitrate.
14	(35) Ammonium sulfate.
15	(36) Hydrogen peroxide.
16	(37) Thionyl chloride.
17	(38) Ethyl acetate.
18	(39) Pseudoephedrine hydrochloride.
19	(b) A person who possesses more than ten (10) grams of ephedrine,
20	pseudoephedrine, or phenylpropanolamine, pure or adulterated,
21	commits a Level 6 felony. However, the offense is a Level 5 felony if
22	the person possessed:
23	(1) a firearm while possessing more than ten (10) grams of
24	ephedrine, pseudoephedrine, or phenylpropanolamine, pure or
25	adulterated; or
26	(2) more than ten (10) grams of ephedrine, pseudoephedrine, or
27	phenylpropanolamine, pure or adulterated, in, on, or within five
28	hundred (500) feet of:
29	(A) school property while a person under eighteen (18) years
30	of age was reasonably expected to be present; or
31	(B) a public park while a person under eighteen (18) years of
32	age was reasonably expected to be present.
33	(c) A person who possesses anhydrous ammonia or ammonia
34	solution (as defined in IC 22-11-20-1) with the intent to manufacture
35	methamphetamine or amphetamine, schedule II controlled substances
36	under IC 35-48-2-6, commits a Level 6 felony. However, the offense
37	is a Level 5 felony if the person possessed:
38	(1) a firearm while possessing anhydrous ammonia or ammonia
39	solution (as defined in IC 22-11-20-1) with intent to manufacture
40	methamphetamine or amphetamine, schedule II controlled
41	substances under IC 35-48-2-6; or
42	(2) anhydrous ammonia or ammonia solution (as defined in



1	IC 22-11-20-1) with intent to manufacture methamphetamine or
2	amphetamine, schedule II controlled substances under
3	IC 35-48-2-6, in, on, or within five hundred (500) feet of:
4	(A) school property while a person under eighteen (18) years
5	of age was reasonably expected to be present; or
6	(B) a public park while a person under eighteen (18) years of
7	age was reasonably expected to be present.
8	(d) Subsection (b) does not apply to a:
9	(1) licensed health care provider, pharmacist, retail distributor,
10	wholesaler, manufacturer, warehouseman, or common carrier or
11	an agent of any of these persons if the possession is in the regular
12	course of lawful business activities; or
13	(2) person who possesses more than ten (10) grams of a substance
14	described in subsection (b) if the substance is possessed under
15	circumstances consistent with typical medicinal or household use,
16	including:
17	(A) the location in which the substance is stored;
18	(B) the possession of the substance in a variety of:
19	(i) strengths;
20	(ii) brands; or
21	(iii) types; or
22 23 24	(C) the possession of the substance:
23	(i) with different expiration dates; or
	(ii) in forms used for different purposes.
25	(e) A person who possesses two (2) or more chemical reagents or
26	precursors with the intent to manufacture a controlled substance
27	commits a Level 6 felony.
28	(f) An offense under subsection (e) is a Level 5 felony if the person
29	possessed:
30	(1) a firearm while possessing two (2) or more chemical reagents
31	or precursors with intent to manufacture a controlled substance;
32	or
33	(2) two (2) or more chemical reagents or precursors with intent to
34	manufacture a controlled substance in, on, or within five hundred
35	(500) feet of:
36	(A) school property while a person under eighteen (18) years
37	of age was reasonably expected to be present; or
38	(B) a public park while a person under eighteen (18) years of
39	age was reasonably expected to be present.
40	(g) A person who sells, transfers, distributes, or furnishes a chemical
41	reagent or precursor to another person with knowledge or the intent that
42	the recipient will use the chemical reagent or precursors to manufacture



1	a controlled substance commits unlawful sale of a precursor, a Level
2	6 felony. However, the offense is a Level 5 felony if the person sells,
3	transfers, distributes, or furnishes more than ten (10) grams of
4	ephedrine, pseudoephedrine, or phenylpropanolamine.
5	(h) This subsection does not apply to a drug containing ephedrine,
6	pseudoephedrine, or phenylpropanolamine that is dispensed under a
7	prescription. A person who:
8	(1) has been convicted of:
9	(A) dealing in methamphetamine (IC 35-48-4-1.1);
10	(B) possession of more than ten (10) grams of ephedrine,
11	pseudoephedrine, or phenylpropanolamine (subsection (b));
12	(C) possession of anhydrous ammonia or ammonia solution (as
13	defined in IC 22-11-20-1) with intent to manufacture
14	methamphetamine or amphetamine (subsection (c));
15	(D) possession of two (2) or more chemical reagents or
16	precursors with the intent to manufacture a controlled
17	substance (subsection (e)); or
18	(E) unlawful sale of a precursor (subsection (g)); or
19	(F) another drug related felony (as defined in
20	IC 35-48-4-18); and
21	(2) not later than seven (7) years from the date the person was
22	sentenced for the offense;
23	knowingly or intentionally possesses ephedrine, pseudoephedrine, or
24	phenylpropanolamine, pure or adulterated, commits possession of a
25	precursor by a methamphetamine offender, a Level 6 felony.
26	SECTION 6. IC 35-48-4-14.7, AS AMENDED BY P.L.193-2013,
27	SECTION 8, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
28	JULY 1, 2016]: Sec. 14.7. (a) This section does not apply to the
29	following:
20	ionowing.
30	(1) Ephedrine or pseudoephedrine dispensed pursuant to a
31	(1) Ephedrine or pseudoephedrine dispensed pursuant to a prescription.
31 32	(1) Ephedrine or pseudoephedrine dispensed pursuant to a prescription.(2) The sale of a drug containing ephedrine or pseudoephedrine
31 32 33	 (1) Ephedrine or pseudoephedrine dispensed pursuant to a prescription. (2) The sale of a drug containing ephedrine or pseudoephedrine to a licensed health care provider, pharmacist, retail distributor,
31 32 33 34	(1) Ephedrine or pseudoephedrine dispensed pursuant to a prescription.(2) The sale of a drug containing ephedrine or pseudoephedrine
31 32 33 34 35	 Ephedrine or pseudoephedrine dispensed pursuant to a prescription. The sale of a drug containing ephedrine or pseudoephedrine to a licensed health care provider, pharmacist, retail distributor, wholesaler, manufacturer, or an agent of any of these persons if the sale occurs in the regular course of lawful business activities.
31 32 33 34 35 36	 Ephedrine or pseudoephedrine dispensed pursuant to a prescription. The sale of a drug containing ephedrine or pseudoephedrine to a licensed health care provider, pharmacist, retail distributor, wholesaler, manufacturer, or an agent of any of these persons if the sale occurs in the regular course of lawful business activities. However, a retail distributor, wholesaler, or manufacturer is
31 32 33 34 35 36 37	 Ephedrine or pseudoephedrine dispensed pursuant to a prescription. The sale of a drug containing ephedrine or pseudoephedrine to a licensed health care provider, pharmacist, retail distributor, wholesaler, manufacturer, or an agent of any of these persons if the sale occurs in the regular course of lawful business activities. However, a retail distributor, wholesaler, or manufacturer is required to report a suspicious order to the state police department
31 32 33 34 35 36 37 38	 Ephedrine or pseudoephedrine dispensed pursuant to a prescription. The sale of a drug containing ephedrine or pseudoephedrine to a licensed health care provider, pharmacist, retail distributor, wholesaler, manufacturer, or an agent of any of these persons if the sale occurs in the regular course of lawful business activities. However, a retail distributor, wholesaler, or manufacturer is required to report a suspicious order to the state police department in accordance with subsection (g).
31 32 33 34 35 36 37 38 39	 Ephedrine or pseudoephedrine dispensed pursuant to a prescription. The sale of a drug containing ephedrine or pseudoephedrine to a licensed health care provider, pharmacist, retail distributor, wholesaler, manufacturer, or an agent of any of these persons if the sale occurs in the regular course of lawful business activities. However, a retail distributor, wholesaler, or manufacturer is required to report a suspicious order to the state police department in accordance with subsection (g). The sale of a drug containing ephedrine or pseudoephedrine
31 32 33 34 35 36 37 38 39 40	 (1) Ephedrine or pseudoephedrine dispensed pursuant to a prescription. (2) The sale of a drug containing ephedrine or pseudoephedrine to a licensed health care provider, pharmacist, retail distributor, wholesaler, manufacturer, or an agent of any of these persons if the sale occurs in the regular course of lawful business activities. However, a retail distributor, wholesaler, or manufacturer is required to report a suspicious order to the state police department in accordance with subsection (g). (3) The sale of a drug containing ephedrine or pseudoephedrine by a person who does not sell exclusively to walk-in customers for
31 32 33 34 35 36 37 38 39	 Ephedrine or pseudoephedrine dispensed pursuant to a prescription. The sale of a drug containing ephedrine or pseudoephedrine to a licensed health care provider, pharmacist, retail distributor, wholesaler, manufacturer, or an agent of any of these persons if the sale occurs in the regular course of lawful business activities. However, a retail distributor, wholesaler, or manufacturer is required to report a suspicious order to the state police department in accordance with subsection (g). The sale of a drug containing ephedrine or pseudoephedrine



1	manufacturer, the person is required to report a suspicious order
2	to the state police department in accordance with subsection (g).
3	(b) The following definitions apply throughout this section:
4	(1) "Constant video monitoring" means the surveillance by an
5	automated camera that:
6	(A) records at least one (1) photograph or digital image every
7	ten (10) seconds;
8	(B) retains a photograph or digital image for at least
9	seventy-two (72) hours;
10	(C) has sufficient resolution and magnification to permit the
11	identification of a person in the area under surveillance; and
12	(D) stores a recorded photograph or digital image at a location
13	that is immediately accessible to a law enforcement officer.
14	(2) "Convenience package" means a package that contains a drug
15	having as an active ingredient not more than sixty (60) milligrams
16	of ephedrine or pseudoephedrine, or both.
17	(3) "Ephedrine" means pure or adulterated ephedrine.
18	(4) "Pharmacy" or NPLEx retailer" means: includes:
19	(A) a pharmacy, as defined in IC 25-26-13-2; or
20	(B) a retailer containing a pharmacy, as defined in
21	IC 25-26-13-2. or
22	(C) a retailer that electronically submits the required
23	information to the National Precursor Log Exchange (NPLEx)
23 24 25	administered by the National Association of Drug Diversion
25	Investigators (NADDI).
26	(5) "Pseudoephedrine" means pure or adulterated
27	pseudoephedrine.
28	(6) "Retailer" means a grocery store, general merchandise store,
29	or other similar establishment. The term does not include a
30	pharmacy or NPLEx retailer.
31	(7) "Suspicious order" means a sale or transfer of a drug
32	containing ephedrine or pseudoephedrine if the sale or transfer:
33	(A) is a sale or transfer that the retail distributor, wholesaler,
34	or manufacturer is required to report to the United States Drug
35	Enforcement Administration;
36	(B) appears suspicious to the retail distributor, wholesaler, or
37	manufacturer in light of the recommendations contained in
38	Appendix A of the report to the United States attorney general
39	by the suspicious orders task force under the federal
40	Comprehensive Methamphetamine Control Act of 1996; or
41	(C) is for cash or a money order in a total amount of at least
12	two hundred dellars (\$200)



1	(8) "Unusual theft" means the theft or unexplained disappearance
2	from a particular pharmacy or NPLEx retailer of drugs containing
3	ten (10) grams or more of ephedrine, pseudoephedrine, or both in
4	a twenty-four (24) hour period.
5	(c) A drug containing ephedrine or pseudoephedrine may be sold
6	only by a pharmacy. or NPLEx retailer. Except as provided in
7	subsection (f), a retailer may not sell a drug containing ephedrine or
8	pseudoephedrine.
9	(d) A pharmacy or NPLEx retailer may sell a drug that contains the
10	active ingredient of ephedrine, pseudoephedrine, or both only if the
11	pharmacy or NPLEx retailer complies with the following conditions:
12	(1) The pharmacy or NPLEx retailer does not sell the drug to a
13	person less than eighteen (18) years of age.
14	(2) The pharmacy or NPLEx retailer does not sell drugs
15	containing more than:
16	(A) three and six-tenths (3.6) grams of ephedrine or
17	pseudoephedrine, or both, to one (1) individual on one (1) day;
18	(B) seven and two-tenths (7.2) grams of ephedrine or
19	pseudoephedrine, or both, to one (1) individual in a thirty (30)
20	day period; or
21	(C) sixty-one and two-tenths (61.2) grams of ephedrine or
22	pseudoephedrine, or both, to one (1) individual in a three
23	hundred sixty-five (365) day period.
24	(3) Before the sale occurs, the pharmacist shall make a
25	professional determination, based on the pharmacist-patient
26	relationship, as to whether there is a legitimate medical and
27	pharmaceutical need for ephedrine or pseudoephedrine
28	before selling ephedrine or pseudoephedrine to an individual.
29	The pharmacist's professional determination may be based on
30	factors that include the following:
31	(A) Prior medication filling history of the individual.
32	(B) Screening of the individual.
33	(C) Other tools that provide professional reassurance to
34	the pharmacist that a legitimate medical and
35	pharmaceutical need for ephedrine or pseudoephedrine
36	exists.
37	(3) (4) The pharmacy or NPLEx retailer requires:
38	(A) the purchaser to produce a valid government issued photo
39	identification card showing the date of birth of the person;
40	(B) the purchaser to sign a written or electronic log attesting
41	to the validity of the information; and



2016

(C) the clerk who is conducting the transaction to initial or

1	alastonia alla occorditta alantini idantification andha lac
2	electronically record the clerk's identification on the log.
3	Records from the completion of a log must be retained for at least
	two (2) years. A law enforcement officer has the right to inspect
4	and copy a log or the records from the completion of a log in
5	accordance with state and federal law. A pharmacy or NPLEx
6	retailer may not sell or release a log or the records from the
7	completion of a log for a commercial purpose. The Indiana
8	criminal justice institute may obtain information concerning a log
9	or the records from the completion of a log from a law
10	enforcement officer if the information may not be used to identify
11	a specific individual and is used only for statistical purposes. A
12	pharmacy or NPLEx retailer that in good faith releases
13	information maintained under this subsection is immune from
14	civil liability unless the release constitutes gross negligence or
15	intentional, wanton, or willful misconduct.
16	(4) (5) The pharmacy or NPLEx retailer maintains a record of
17	information for each sale of a nonprescription product containing
18	pseudoephedrine or ephedrine. Required information includes:
19	(A) the name and address of each purchaser;
20	(B) the type of identification presented;
21	(C) the governmental entity that issued the identification;
22	(D) the identification number; and
23	(E) the ephedrine or pseudoephedrine product purchased,
24	including the number of grams the product contains and the
25	date and time of the transaction.
26	(5) (6) Beginning January 1, 2012, a pharmacy or NPLEx retailer
27	shall, except as provided in subdivision (6), (7), before
28	completing a sale of an over-the-counter product containing
29	pseudoephedrine or ephedrine, electronically submit the required
30	information to the National Precursor Log Exchange (NPLEx)
31	administered by the National Association of Drug Diversion
32	Investigators (NADDI), if the NPLEx system is available to
33	pharmacies or NPLEx retailers in the state without a charge for
34	accessing the system. The pharmacy or NPLEx retailer may not
35	complete the sale if the system generates a stop sale alert,
36	including a stop sale alert for an individual convicted of a
37	drug related felony reported under IC 10-11-2-31.5.
38	(6) (7) If a pharmacy or NPLEx retailer selling an
39	over-the-counter product containing ephedrine or
40	pseudoephedrine experiences mechanical or electronic failure of
41	the electronic sales tracking system and is unable to comply with
	the electronic suics trucking system and is unable to comply with

the electronic sales tracking requirement, the pharmacy or NPLEx



retailer shall maintain a written log or an alternat	tive electronic
recordkeeping mechanism until the pharmacy or N	PLEx retaile s
is able to comply with the electronic sales tracking	g requirement
(7) (8) The pharmacy or NPLEx retailer stores the	drug behind a
counter in an area inaccessible to a customer o	or in a locked
display case that makes the drug unavailable t	to a customer
without the assistance of an employee.	

- (e) A person may not purchase drugs containing more than:
 - (1) three and six-tenths (3.6) grams of ephedrine or pseudoephedrine, or both, on one (1) day;
 - (2) seven and two-tenths (7.2) grams of ephedrine or pseudoephedrine, or both, in a thirty (30) day period; or
 - (3) sixty-one and two-tenths (61.2) grams of ephedrine or pseudoephedrine, or both, in a three hundred sixty-five (365) day period.

These limits apply to the total amount of base ephedrine and pseudoephedrine contained in the products and not to the overall weight of the products.

- (f) This subsection only applies to convenience packages. A retailer may sell convenience packages under this section without complying with the conditions listed in subsection (d):
 - (1) after June 30, 2013; and
 - (2) before January 1, 2014.

A retailer may not sell drugs containing more than sixty (60) milligrams of ephedrine or pseudoephedrine, or both in any one (1) transaction. A retailer who sells convenience packages must secure the convenience packages behind the counter in an area inaccessible to a customer or in a locked display case that makes the drug unavailable to a customer without the assistance of an employee. A retailer may not sell a drug containing ephedrine or pseudoephedrine after December 31, 2013.

- (g) A retail distributor, wholesaler, or manufacturer shall report a suspicious order to the state police department in writing.
- (h) Not later than three (3) days after the discovery of an unusual theft at a particular retail store, the pharmacy or NPLEx retailer shall report the unusual theft to the state police department in writing. If three (3) unusual thefts occur in a thirty (30) day period at a particular pharmacy, or NPLEx retailer, the pharmacy or NPLEx retailer shall, for at least one hundred eighty (180) days after the date of the last unusual theft, locate all drugs containing ephedrine or pseudoephedrine at that particular pharmacy or NPLEx retailer behind a counter in an area inaccessible to a customer or in a locked display case that makes the



drug unavailable to customers without the assistance of an employee.

after February 1, 2005, that is more stringent than this section.

(i) A unit (as defined in IC 36-1-2-23) may not adopt an ordinance

(j) A person who knowingly or intentionally violates this section

5	commits a Class C misdemeanor. However, the offense is a Class A
6	misdemeanor if the person has a prior unrelated conviction under this
7	section.
8	(k) A pharmacy or NPLEx retailer that uses the electronic sales
9	tracking system in accordance with this section is immune from civil
10	liability for any act or omission committed in carrying out the duties
11	required by this section, unless the act or omission was due to
12	negligence, recklessness, or deliberate or wanton misconduct. A
13	pharmacy or NPLEx retailer is immune from liability to a third party
14	unless the pharmacy or NPLEx retailer has violated a provision of this
15	section and the third party brings an action based on the pharmacy's or
16	NPLEx retailer's violation of this section.
17	(1) The following requirements apply to the NPLEx:
18	(1) Information contained in the NPLEx may be shared only with
19	law enforcement officials.
20	(2) A law enforcement official may access Indiana transaction
21	information maintained in the NPLEx for investigative purposes.
22	(3) NADDI may not modify sales transaction data that is shared
23	with law enforcement officials.
24	(4) At least one (1) time per week, NADDI shall forward day.
25	Indiana data contained in the NPLEx including data concerning
26	a for the previous calendar day shall be forwarded transaction
27	that could not be completed due to the issuance of a stop sale
28	alert, to the state police department.
29	SECTION 7. IC 35-48-4-18 IS ADDED TO THE INDIANA CODE
30	AS A NEW SECTION TO READ AS FOLLOWS [EFFECTIVE JULY
31	1, 2016]: Sec. 18. (a) As used in this section, "drug related felony"
32	means a felony conviction for an offense described in:
33	(1) sections 1 through 11.5 of this chapter; or
34	(2) sections 13 through 14.7 of this chapter.
35	(b) The court shall report any conviction for a drug related
36	felony to the state police department for purposes of
37	IC 10-11-2-31.5. The report must contain at least the following
38	information:
39	(1) The convicted individual's full name.
40	(2) The convicted individual's date of birth.
41	(3) The convicted individual's driver's license number or state
42	personal identification number.



2016

1 2

3

1	(4) The Indiana Code citation and associated cause number of
2	the drug related felony of which the individual was convicted.
3	(5) The date the individual was convicted of the drug related
4	felony.

